Lonel

Quick links to important sections

Lonel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lonel

Property Description
Active Ingredient Olmesartan Medoxomil
Form Oral Tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Common Purpose Systematically lowering elevated blood pressure
Origin Synthetic molecule

Lonel is the trade designation for the pharmaceutical agent Olmesartan Medoxomil, a synthetic drug classified as an Angiotensin II Receptor Blocker (ARB), broadly categorized as an Antihypertensive medicine. This medication is specifically designed to interfere with a natural system in the body that controls blood pressure, thereby providing systemic cardiovascular support. It is generally intended for managing conditions where sustained blood pressure control is necessary, and is typically available as a prescription-only (Rx) product.


What Type of Medicine is Lonel?

Lonel is a synthetic molecule whose classification as an Angiotensin II Receptor Blocker (ARB) is clinically recognized for its targeted effect on the cardiovascular system. ARBs work by selectively targeting specific receptor sites in the body. This drug belongs to the class of agents that prevent the potent hormone angiotensin II from binding to and activating the AT1 receptor. This precise inhibition is a key feature of ARBs, offering a different intervention point compared to other antihypertensive classes.


Composition and Form: Understanding Olmesartan Medoxomil

The primary component of Lonel is Olmesartan Medoxomil, delivered predominantly in the form of an oral tablet and formulated as a single active ingredient product (monotherapy). The active substance is referred to as a prodrug because the body's digestive processes convert it into the therapeutically active compound, Olmesartan, after it is ingested, maximizing the drug's intended action. For instance, Lonel is used as a foundational medication for patients requiring the specific action of a single ARB to regulate blood flow dynamics.


What is the General Purpose of Taking Lonel?

The general purpose of Lonel is to systematically reduce and stabilize elevated blood pressure, thereby mitigating chronic strain on the cardiovascular system. By promoting the relaxation and widening of the arteries (vasodilation), the medication reduces the overall resistance in the circulatory system, making it easier for blood to flow. For the patient, this means the medication helps protect vital organs, including the heart and kidneys, from damage associated with prolonged, uncontrolled high pressure.

What side effects are possible with Lonel?

Possible side effects and safety information for Lonel

Lonel (Olmesartan Medoxomil) is associated with adverse reactions that regulatory documents classify by frequency and affected physiological system.

Frequency Classification Examples of Officially Listed Adverse Reactions
Common (1% to 10%) Dizziness, headache, back pain, bronchitis, nasopharyngitis, diarrhea.
Uncommon/Rare Vertigo, tachycardia, hypotension, angioedema.
Incidence Not Known Sprue-like enteropathy, rhabdomyolysis, alopecia.

Adverse reactions are grouped into System-Organ Classes (SOC), including Nervous System Disorders (dizziness, headache), Gastrointestinal Disorders (diarrhea, abdominal pain), and Vascular Disorders (hypotension).

Serious Adverse Reactions and Constraints

Official labeling highlights severe safety concerns, notably Fetal Toxicity, which is a contraindication during the second and third trimesters of pregnancy and may cause injury or death to the fetus. A specific serious reaction documented in post-marketing experience is Sprue-like Enteropathy, a condition characterized by severe, chronic diarrhea and substantial weight loss that may develop months to years after starting treatment.

Safety statements for special populations include the requirement to avoid use in patients with severely impaired renal function. Furthermore, co-administration with aliskiren is contraindicated in patients with diabetes due to an increased risk of severe adverse events, including hyperkalemia and renal impairment. Symptomatic hypotension may be anticipated, particularly in volume- or salt-depleted patients, often occurring upon treatment initiation.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented manifestations of overdose and the required emergency actions as stated in government regulatory sources for Olmesartan Medoxomil (Lonel).

The most likely manifestation of an overdose is hypotension (severely low blood pressure), resulting from an exaggerated therapeutic effect. This may be accompanied by tachycardia (rapid heart rate). Bradycardia (slow heart rate) is also documented as a possible manifestation that could occur due to parasympathetic stimulation. A major consequence of profound hypotension may be shock.

Required Emergency Actions

Regulatory authorities mandate that any suspected overdose requires immediately seeking medical attention. Individuals should call a Poison Control Center without delay. Treatment for overdose is symptomatic and supportive, aiming to manage the low blood pressure.

Management and Procedural Notes

  • In cases of symptomatic hypotension, the official management includes placing the patient in a supine position and initiating an intravenous infusion of normal saline (or other appropriate volume expander).
  • It is explicitly stated in official labeling that no specific antidote for Olmesartan Medoxomil is known.
  • Due to the drug’s high plasma protein binding, hemodialysis is unlikely to be of benefit in the management of overdose.

The regulatory profile clearly defines the risk as cardiovascular depression and dictates that all interventions focus on supportive measures.

Therapeutic Uses of Lonel

Lonel is a prescription medication generally applied in contexts where additional symptomatic support is needed for long-term cardiovascular health management.

Lonel’s Therapeutic Domains

Lonel is commonly used to help with managing essential hypertension (high blood pressure) and is considered relevant for easing the risk associated with conditions characterized by periods of heightened symptoms, specifically reducing the risk of stroke and supporting kidney function for those with Type 2 diabetes and high blood pressure.

When applied in clinical settings, Lonel may be applied in addressing the effort to achieve stable blood pressure, which helps address symptom clusters related to systemic imbalance and physiological strain on the cardiovascular system. When used as part of a therapeutic plan, this assists with maintaining functional stability and contributes to improved day-to-day comfort. This therapeutic approach offers symptomatic relief that helps patients cope more steadily with their condition.


Quick Fact: Supports Easing Physiological Strain

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lonel — official regulatory information

Eligibility scope

Populations for whom use is allowed (as stated in label): Patients in need of neutropenia treatment following cytotoxic chemotherapy, and females (post-menarche, non-pregnant) requiring emergency contraception.

Populations for whom use is not recommended (if applicable): Patients with severe hepatic dysfunction (emergency contraceptive product), those at risk of ectopic pregnancy, or those with severe malabsorption syndromes. The neutropenia product is not recommended for patients with certain myeloid malignancies (e.g., Chronic Myeloid Leukaemia or Myelodysplastic Syndromes) as safety and efficacy are not established.

Populations for whom use is contraindicated: Individuals with a known hypersensitivity to the active substance or any excipients. Also, persons with rare hereditary problems of fructose or galactose intolerance due to the composition of certain products. Use is contraindicated in the case of known or suspected pregnancy (emergency contraceptive product).

Age-related eligibility rules: The neutropenia product is indicated for adults and children (typically 2 years and older). The emergency contraceptive product is not intended for prepubertal children or postmenopausal women.

Condition-specific eligibility rules: Use is restricted in cases of severe hepatic dysfunction. Treatment with the neutropenia product should be approached with caution in patients with sickle cell anaemia.

Pregnancy and lactation eligibility status (if explicitly documented): Use is prohibited or contraindicated during pregnancy (depending on the specific product). Breast-feeding women using the neutropenia product should discontinue nursing, while those using the emergency contraceptive product may reduce infant exposure by avoiding nursing for at least 8 hours after administration.

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Contraindicated, Not Recommended, Should be Avoided, Use Not Established.

Regulatory basis (EMA / FDA / etc.): European (SmPC) and US (FDA) regulatory documents.

Eligibility-context constraints (as defined in official documents): Clinical state, Prior history, Metabolic/Genetic disorders, Allergic status, and Developmental age.

Resulting eligibility structure

Official eligibility statements:

  • The most severe restriction is Contraindication due to hypersensitivity, known or suspected pregnancy, and specific hereditary metabolic disorders.
  • Use is not recommended or avoided in specific clinical scenarios, such as severe liver impairment, risk of ectopic pregnancy, or for patients with certain myeloid leukemias where safety has not been investigated.
  • Age restrictions apply, confirming no relevant use for prepubertal children and implying adult use for most populations unless pediatric efficacy has been explicitly established and documented.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define the eligible population by establishing strict rules against use in specific medical and physiological states. This profile is defined by definitive contraindications concerning allergic reactions and certain metabolic diseases, alongside not recommended classifications for severe organ dysfunction or pre-existing malignancy types. Overall eligibility is tightly constrained to populations without these explicit conditions to ensure appropriate use as defined by governmental drug authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lonel (Olmesartan Medoxomil) documents interaction patterns primarily related to additive pharmacodynamic effects and specific exposure alterations. These constraints are based on government regulatory risk classifications.

Interaction Classification Interacting Agents / Conditions
Contraindicated Combination Aliskiren in patients with diabetes. This dual inhibition of the Renin-Angiotensin System (RAS) is formally associated with increased risks of hypotension, hyperkalemia, and renal function changes. The combination is also avoided in patients with renal impairment.
Exposure Modification Colesevelam Hydrochloride reduces the systemic concentration of olmesartan. A procedural constraint states that administering olmesartan at least 4 hours before Colesevelam Hydrochloride may mitigate this reduction in exposure.
Pharmacodynamic Risk Agents that Increase Serum Potassium (e.g., potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium) elevate the documented risk of hyperkalemia.
Drug-Drug Effect Lithium co-administration is reported to increase serum lithium concentrations and the risk of toxicity. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may cause renal function deterioration and reduce the blood pressure-lowering effect of Lonel.

These documented constraints organize the product's official interaction structure. The risk of NSAID-related renal deterioration is explicitly noted to be greater in specific populations, including the elderly and those who are volume-depleted.

Mechanism of Action

How Lonel Works: Mechanism of Action

Lonel's primary effect is exerted through the non-selective inhibition of Cyclooxygenase (COX) enzymes—specifically COX-1 and COX-2. This action blocks the initial molecular step in the Arachidonic Acid Cascade, preventing the synthesis of key signaling molecules called prostaglandins and thromboxanes. This modification of early molecular steps initiates the subsequent physiological cascade.

By limiting the systemic production of pro-inflammatory prostaglandins, Lonel engages mechanisms that result in the attenuation of elevated physiological responses at injury sites. This modulation of mediator activity decreases the local sensitization of nociceptors and modulates the body's thermoregulatory set-point.

A distinct portion of the mechanism targets the hypothalamus in the central nervous system (CNS). Here, Lonel inhibits COX activity to suppress the synthesis of Prostaglandin E2, which influences the downward regulation of the hypothalamic temperature set-point. This action modulates the effect of dysregulated signaling on the body's core temperature control.

Dosage and Administration Information

How to Use Lonel

Lonel (Olmesartan Medoxomil) is designated for oral administration, predominantly supplied in tablet strengths of 5 mg, 20 mg, and 40 mg. The medicine is taken once daily, a frequency pattern established because it is recognized that there is no increased therapeutic benefit from dividing the total daily dose. Administration can occur with or without food, though taking the medication at approximately the same time each day is generally advised to ensure procedural consistency.

Official Dosing Regimens

For adults, the usual starting dose is 20 mg once daily. If further adjustment is deemed necessary, the dose may be increased, or titrated, after a period of approximately two weeks, up to a maximum official dose of 40 mg once daily. An extemporaneously prepared oral suspension is an official form of administration for patients, such as children, who may be unable to swallow the solid tablets.

Population-Specific Use Constraints

Specific constraints exist for specific populations. For adults with moderate renal or hepatic impairment, the maximum daily dose is restricted and should generally not exceed 20 mg once daily. For patients who are volume-depleted, a lower starting dose should be considered and initiated under close procedural observation. Pediatric use (ages 6 to 16) follows a weight-based dosing schedule, starting at 10 mg or 20 mg depending on the child’s body weight category.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lonel


Evidence for use in Managing Essential Hypertension

Research examining the agent for essential hypertension (high blood pressure) primarily relies on short-term randomized controlled trials (RCTs). These studies compared the agent against a placebo or active comparators. The primary outcomes research examined involved measuring changes in both Systolic and Diastolic Blood Pressure (SBP and DBP) in adult patients over defined time intervals, typically 8 to 12 weeks.

Studies reported measurements showing that a certain proportion of trial participants reached pre-defined target blood pressure goals within the observed time periods. However, long-term effects are not fully established for this specific agent. The evidence for its relationship to hard outcomes (such as stroke or heart attack) over many years is largely extrapolated from the ARB drug class, as dedicated primary outcome trials for this agent in the general hypertensive population are limited.


Evidence for use in Supporting Kidney Function

The agent was studied for long-term outcomes in adult patients who have both Type 2 diabetes and hypertension. Findings described patterns related to the time to onset of microalbuminuria (an early sign of kidney strain) observed in some studies. When research examined composite long-term outcomes, such as the progression to End-Stage Renal Disease (ESRD), the findings were mixed.


What is Still Uncertain About Lonel Research

Current research contributes to the broader evidence landscape, but limitations are acknowledged. Long-term effects are not fully established for all potential outcomes, as the core efficacy trials for blood pressure lowering were short-term. Subgroup findings are uncertain or require careful interpretation in certain high-risk populations, particularly regarding long-term cardiovascular outcomes in diabetic patients, due to mixed findings and certain reported study results in dedicated long-term trials. Data for children younger than 6 years of age and patients with very advanced kidney failure remain insufficient.

Key Studies & References

  1. Public Assessment Report Scientific discussion Olmesartan medoxomil (European Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Lonel (FAQ)

Q: Is Lonel known to cause weight changes?

A: According to official product information, weight changes are not listed as a common or uncommon side effect of Lonel monotherapy. However, a serious, though rare, adverse reaction called Sprue-like Enteropathy is characterized by severe, chronic diarrhea and substantial weight loss, which typically develops after many months or years of use.


Q: How long does it usually take for Lonel to start working?

A: The blood pressure-lowering effect of Lonel (olmesartan medoxomil) usually becomes substantial within about two weeks of beginning treatment. The medication reaches its maximum intended effect after approximately eight weeks of consistent daily use.


Q: Can Lonel affect sleep patterns?

A: Official labeling, particularly for combination products containing olmesartan, indicates that sleep disturbance is a reported adverse reaction. A persistent change in sleep patterns is a reported concern that can be discussed with a healthcare provider.


Q: Are there any common foods or drinks that should be avoided while taking Lonel?

A: Lonel can be taken with or without food. However, taking alcohol with Lonel may increase its blood pressure-lowering effect, increasing the risk of symptoms like dizziness. Regulatory warnings indicate that Lonel is known to interact with potassium-containing salt substitutes or supplements.


Q: Is it normal to feel tired or dizzy after starting Lonel?

A: Yes, dizziness is listed as a common side effect, meaning it may affect up to 1 in 10 people. The official product information also includes tiredness or fatigue as common adverse reactions. Regulatory documents indicate that these effects may be observed when therapy is initiated.


Q: Can older adults use Lonel?

A: No general dose adjustment is usually required for elderly people (aged 65 years and older). However, regulatory documents highlight that this population has an increased risk of kidney function changes when Lonel is taken alongside certain pain relievers, and monitoring by a healthcare provider may be necessary.


Q: Is there a generic version of Lonel available?

A: Yes, the active ingredient in Lonel is olmesartan medoxomil, which is widely available as a generic medication. The generic form contains the same active compound and meets established criteria for interchangeability with the brand-name product.


Q: How long does Lonel stay in your system after the last use?

A: Official pharmacological data indicates that the active compound, olmesartan, has an average elimination half-life of 12 to 18 hours. A half-life is the time it takes for the concentration of the substance in the body to be reduced by half.


Q: Do studies suggest Lonel is a long-term treatment or short-term?

A: Lonel is approved and indicated for the long-term management of essential hypertension (high blood pressure). While early clinical trials focused on short-term efficacy, the drug is intended for sustained, chronic administration to control blood pressure over time.


Q: What should be done if a dose of Lonel is missed?

A: Official patient information states that a double dose should not be taken to make up for a missed one. The medicine is intended to be continued by taking the next scheduled dose at the usual time the following day.


Q: Is Lonel a controlled substance?

A: No, Lonel (olmesartan medoxomil) is a prescription medication classified as an Angiotensin II Receptor Blocker (ARB). It is not listed or categorized as a controlled substance by regulatory agencies.


Q: Are there any specific lifestyle changes that might help Lonel work better?

A: Regulatory information indicates that managing high blood pressure is part of a comprehensive health strategy. The context of risk management often includes consideration of factors like limited sodium intake and physical activity.


Q: Can Lonel cause changes in mood or anxiety?

A: Official adverse event reports list depression as a possible adverse reaction associated with Lonel. Other effects on anxiety or mood are not explicitly detailed in the common or uncommon side effect lists.


Q: Is it true that Lonel can interact with grapefruit?

A: There is no known interaction between Lonel (olmesartan monotherapy) and grapefruit. However, Lonel is sometimes used in combination with other medications, and grapefruit or grapefruit juice may interact with the other component of the combination product.


Q: Does Lonel contain any ingredients that might cause an allergic reaction?

A: Yes, regulatory information strictly contraindicates the use of Lonel in individuals with a known hypersensitivity to the active substance (olmesartan medoxomil) or any of the inactive ingredients, known as excipients. The full list of excipients is available in the official patient leaflet.


Q: Does Lonel have a sedative effect?

A: Lonel is not reported to have a direct sedative effect. However, patients should be aware that common side effects like dizziness and fatigue may occur, which could impair the ability to react or feel drowsy.


Q: How effective is Lonel for treating its main indication according to clinical trials?

A: Clinical trial evidence confirms that Lonel is significantly more effective than a placebo at reducing both systolic and diastolic blood pressure. Studies report that a clear proportion of participants successfully achieved pre-defined target blood pressure goals during the trial periods.


Q: Are there any restrictions on driving or operating machinery while on Lonel?

A: Official warnings advise caution when driving or operating machinery. This is because side effects such as dizziness or fatigue may occur with blood pressure-lowering therapy and could impair your ability to react safely.


Q: How is Lonel packaged and supplied?

A: Lonel is officially supplied as film-coated tablets, typically packaged in sealed blister packs or high-density polyethylene (HDPE) bottles. Regulatory rules require that the medication be stored in its original container to ensure protection from moisture and light.


Q: Does Lonel have any effects on blood sugar levels?

A: Lonel's official interaction profile notes constraints regarding its use with certain other drugs in patients who have diabetes. Official information regarding its use with certain other drugs highlights specific constraints for patients with diabetes.


Q: Is Lonel recommended for people who have heart conditions?

A: Lonel is used to treat high blood pressure, which is a cardiovascular condition. However, official regulatory precautions note that the drug should be used carefully in patients with certain heart conditions, such as severe congestive heart failure, whose blood pressure stability is critical and requires careful monitoring.


Q: How quickly do the side effects of Lonel typically start and stop?

A: Common side effects like headache or dizziness often occur shortly after beginning treatment. Conversely, a serious post-marketing adverse reaction called Sprue-like Enteropathy is explicitly noted to develop much later, potentially months to years after starting the medication.


Q: How does the official research categorize the safety of Lonel?

A: Official research categorizes safety by listing adverse reactions based on their frequency (such as common or rare) and severity. The label details serious safety concerns, including Fetal Toxicity (which is a contraindication during pregnancy) and specific post-marketing reports like Sprue-like Enteropathy.


Q: What happens if Lonel is taken with alcohol?

A: Official warnings state that consuming alcohol with Lonel may result in an additive effect that lowers blood pressure. This could increase the risk of side effects like dizziness, lightheadedness, or fainting, particularly when initiating therapy.


Q: How does Lonel affect mental clarity or focus?

A: Official product information lists side effects such as headache and dizziness, which may impair mental clarity or focus. Additionally, a possible side effect reported in adverse event data is depression, which can also impact concentration.

How should Lonel be stored and disposed of?

The storage and disposal of Lonel (Olmesartan Medoxomil) tablets must strictly follow the conditions defined in official regulatory labeling to ensure product stability and safety.

Mandatory Storage and Protection

The tablets must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with permitted short-term excursions. It is essential to keep the medicine in its original container, ensuring it is tightly closed to protect it from excessive moisture, heat, and direct light. The product should not be frozen.

Disposal and Safety

All Lonel tablets must be stored out of the reach and sight of children. Unused or expired medication must be disposed of according to local pharmaceutical waste regulations or via a community drug take-back program. It should not be flushed down a toilet or discarded in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lonel found in:

A-Z Index: